Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BZ019 in R/R Large B-cell Lymphoma
NCT04250324Phase 1Unknown
- Sponsor
- Shanghai Cell Therapy Group
- Start
- Nov 2019
- Primary completion
- Aug 2022
- Modality
- Gene Editing, Prophylactic Vaccines, Gene Silencing
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of BZ019 in diffuse large B-cell lymphoma (DLBCL), sponsored by Shanghai Cell Therapy Group. Primary endpoints: Dose-Limiting Toxicity at 28 days and Maximum Tolerated Dose at 28 days. Status: unknown.
02
Drugs
BZ019
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT04250324.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04250324.